Healthcare giant Johnson & Johnson (JNJ - ) on Tuesday reported first-quarter earnings that were lower than last year though still beat analysts' expectations, even as it faces litigation over allegations that its iconic talc baby powder contained asbestos, and it battles increased competition from generic prostate cancer drugs.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,